Buy & Sell Heron Therapeutics Inc (HRTX) – Heron Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $160.79MMarket Cap
- HealthSector
- -37.84%3M Drawdown
- $258.69MEnterprise Value
- -Dividend Yield
- 31% Buy | 69% SellTrading Activity
- 16 daysTypical Hold Time
Heron Therapeutics Inc (HRTX) is currently valued at a market capitalization of $160.79M, with an enterprise value of $258.69M. Over the past 52 weeks, Heron Therapeutics Inc has traded between a low of $0.75 and a high of $2.23, highlighting its annual price range. Over the past three months, Heron Therapeutics Inc has recorded a drawdown of -37.84%, reflecting recent price volatility. On average, investors hold Heron Therapeutics Inc for approximately 16 days, indicating typical investor behavior on the platform.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Most Recent News
ESR1-mutated metastatic breast cancer market to grow 9.6% CAGR with new oral SERDs and targeted therapies.
The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies ...

Exosens doubles cooled infrared camera production to meet rising demand in counter-drone systems.
Exosens plans to double its production capacity for cooled infrared cameras in 2026 to meet growing global demand, especially for long-range surveillance and counter-drone applications. These cameras, made in France, are critical for detecting drone ...

Western Star Resources advances U.S. tungsten supply with defense contract bid and European investor deal
Western Star Resources submitted an application to the U.S. Defense Industrial Base Consortium to supply tungsten, a critical mineral, from its past-producing Rowland property in Nevada. This move aligns with U.S. efforts to reduce reliance on Chines...
